Locally Advanced Rectal Cancer
Conditions
Brief summary
This study enrolled patients with locally advanced rectal cancer. The experimental group received irinotecan liposomes combined with standard total neoadjuvant therapy (TNT), while the control group received standard TNT. The study endpoints were the complete response rate (cCR + pCR), 3-year event-free survival (EFS) rate, and overall survival (OS). The aim was to compare the efficacy and safety of irinotecan liposomes combined with or without standard TNT.
Interventions
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years and ≤ 75 years, both male and female are eligible; 2. Histologically confirmed rectal adenocarcinoma; 3. Clinical stage assessed by MRI as T3-4 or N+ (according to the 8th edition of the AJCC); 4. Distance from the lower edge of the tumor to the anal verge ≤ 10 cm; 5. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1; 6. UGT1A1\*6 and UGT1A1\*28 gene phenotypes are either wild-type (GG+6/6) or single-site mutant (GG+6/7 or GA+6/6); 7. No prior anti-tumor treatment for rectal cancer, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.; 8. Normal function of major organs.
Exclusion criteria
1. Previous or ongoing treatment for rectal cancer, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. 2. Known MSI-H (high microsatellite instability) by genetic testing or dMMR (deficient mismatch repair) by immunohistochemistry. 3. Known hypersensitivity, allergic reaction, or contraindication to irinotecan liposomes/vehicle, irinotecan, other liposomal products, 5-FU, leucovorin, oxaliplatin, or any of these agents. 4. Uncontrolled cardiac symptoms or disease. 5. Severe infection (CTCAE \> Grade 2) within 4 weeks prior to the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications; baseline chest imaging showing active pulmonary inflammation; signs and symptoms of infection within 14 days prior to the first use of the study drug or requiring oral or intravenous antibiotic therapy, excluding prophylactic use of antibiotics. 6. Severe gastrointestinal dysfunction (inflammation or diarrhea greater than Grade 1).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response rate（CR） | cCR: before the surgery, and up to 4 weeks after the end of completation of total neoadjuvant therapy (TNT) for cCR. pCR: after the surgery. | Clinical Complete Response rate（cCR）+ Pathological Complete Response rate （pCR） |
Secondary
| Measure | Time frame |
|---|---|
| 3-year event-free survival (3y-EFS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. |
Countries
China
Contacts
Primary ContactJi ZHU
Outcome results
None listed